Pfizer hails phase 2 data as proof that GBS maternal vaccine offers 'meaningful protection'

With Pfizer’s entry in the respiratory syncytial virus (RSV) race soaking up most of the press attention, it’s easy to forget that the Big Pharma has other vaccines in the works. They include a maternal vaccine for group B streptococcus (GBS), which has posted some positive data after a long period of radio silence.